Study Title
ARST1431: A randomized Phase III study of vincristine& dactinomycin& cyclophosphamide (VAC) alternating with vincristine and irinotecan (VI) versus VAC/VI plus temsirolimus (TEM) in patients with intermediate risk (IR) rhabdomyosarcoma (RMS)
Protocol ID
ARST1431
Condition/s
Alveolar Rhabdomyosarcoma
Botryoid-Type Embryonal Rhabdomyosarcoma
Embryonal Rhabdomyosarcoma
Rhabdomyosarcoma
Sclerosing Rhabdomyosarcoma
Spindle Cell Rhabdomyosarcoma
Botryoid-Type Embryonal Rhabdomyosarcoma
Embryonal Rhabdomyosarcoma
Rhabdomyosarcoma
Sclerosing Rhabdomyosarcoma
Spindle Cell Rhabdomyosarcoma
Diagnosis Stage
New diagnosis
Sponsor
National Cancer Institute (NCI)
Links
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 3
Age Eligibility
under 40 years of age
International registry ID's
NCT02567435
| Study Title | ARST1431: A randomized Phase III study of vincristine& dactinomycin& cyclophosphamide (VAC) alternating with vincristine and irinotecan (VI) versus VAC/VI plus temsirolimus (TEM) in patients with intermediate risk (IR) rhabdomyosarcoma (RMS) |
|---|---|
| Protocol ID | ARST1431 |
| Disease (Sub Disease) | Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Rhabdomyosarcoma Sclerosing Rhabdomyosarcoma Spindle Cell Rhabdomyosarcoma |
| Diagnosis Stage | New diagnosis |
| Sponsor | National Cancer Institute (NCI) |
| Links | https://clinicaltrials.gov/ct2/show/NCT02567435 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 09/12/2016 |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | under 40 years of age |
| International registry ID's | NCT02567435 |